Alpha 2.0
Login Register
» Articles » PMID: 24670172

Overcoming Drug Resistance in ALK-rearranged Lung Cancer

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2014 Mar 28
PMID 24670172
Citations 12
Authors
Roman K Thomas
Affiliations
Soon will be listed here.
Citing Articles

The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions.

Rina A, Maffeo D, Minnai F, Esposito M, Palmieri M, Serio V Cancers (Basel). 2024; 16(16).

PMID: 39199653 PMC: 11352260. DOI: 10.3390/cancers16162882.

Recent advances in non-small cell lung cancer targeted therapy; an update review.

Araghi M, Mannani R, Maleki A, Hamidi A, Rostami S, Safa S Cancer Cell Int. 2023; 23(1):162.

PMID: 37568193 PMC: 10416536. DOI: 10.1186/s12935-023-02990-y.

N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition.

Zhang X, Chen J, Jiang S, He S, Bai Y, Zhu L Oxid Med Cell Longev. 2019; 2019:7561879.

PMID: 31354912 PMC: 6636470. DOI: 10.1155/2019/7561879.

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.

Kim S, Kim S, Kim D, Kim M, Keam B, Kim T Cancer Res Treat. 2019; 51(3):1231-1240.

PMID: 30653748 PMC: 6639241. DOI: 10.4143/crt.2018.486.

MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.

Xue F, Liang Y, Li Z, Liu Y, Zhang H, Wen Y Oncol Lett. 2018; 15(1):813-820.

PMID: 29399149 PMC: 5772877. DOI: 10.3892/ol.2017.7399.